EudraCT Number: 2021-006326-48 Sponsor Protocol Number: CO43810 Start Date: 2022-09-27
Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
Full Title: A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AN...
Medical condition: CD20 positive B-Cell Non-Hodgkin Lymphoma
Disease: Version SOC Term Classification Code Term Level
23.1 100000004864 10084346 B-cell non-Hodgkin's lymphoma LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: ES (Ongoing) DK (Ongoing) DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005504-36 Sponsor Protocol Number: ABNCoV2-03 Start Date: 2022-09-19
Sponsor Name: Bavarian Nordic A/S
Full Title: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Doubl...
Medical condition: COVID-19 disease
Disease: Version SOC Term Classification Code Term Level
23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date: 2022-09-02
Sponsor Name: Adeptio Pharmaceuticals Ltd
Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
Medical condition: Tardive dyskinesia
Disease: Version SOC Term Classification Code Term Level
21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HR (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005573-12 Sponsor Protocol Number: LP0162-1335 Start Date: 2022-09-02
Sponsor Name: LEO Pharma A/S
Full Title: A single (assessor) blinded, randomised, parallel-group, monotherapy trial to evaluate the pharmacokinetic and safety of tralokinumab in children (age 2 to
Medical condition: Atopic dermatitis
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10003639 Atopic dermatitis LLT
Population Age: Children, Under 18 Gender: Male, Female
Trial protocol: CZ (Ongoing) NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-004453-23 Sponsor Protocol Number: R3767-ONC-2011 Start Date: 2022-08-30
Sponsor Name: Regeneron Pharmaceuticals, Inc.
Full Title: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
Medical condition: Cutaneous Melanoma
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) FR (Ongoing) IE (Ongoing) ES (Ongoing) BE (Ongoing) PL (Ongoing) AT (Ongoing) NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005178-25 Sponsor Protocol Number: 216152 Start Date: 2022-08-22
Sponsor Name: GlaxoSmithKline Biologicals SA
Full Title: A Phase 1/2a, observer-blind, randomized, controlled, two-stage, multi-country study to evaluate the safety, reactogenicity, and immune response of the trivalent vaccine against invasive nontyphoid...
Medical condition: Healthy volunteers (prevention of invasive nontyphoidal Salmonella disease and typhoid fever)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: BE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-004183-21 Sponsor Protocol Number: IP-001-18 Start Date: 2022-08-19
Sponsor Name: Iperboreal Pharma Srl
Full Title: A Study to Evaluate the EffIcacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis
Medical condition: End-Stage Renal Disease (ESRD)
Disease: Version SOC Term Classification Code Term Level
21.0 10038359 - Renal and urinary disorders 10077512 End stage renal disease PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) DK (Ongoing) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-004979-14 Sponsor Protocol Number: AR-320-003 Start Date: 2022-08-18
Sponsor Name: Aridis Pharmaceuticals, Inc.
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention o...
Medical condition: Prevention of nosocomial pneumonia
Disease: Version SOC Term Classification Code Term Level
21.1 100000004862 10052596 Nosocomial pneumonia LLT
Population Age: Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: ES (Ongoing) FR (Ongoing) BE (Ongoing) NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005713-13 Sponsor Protocol Number: 21102 Start Date: 2022-08-16
Sponsor Name: ACELYRIN, INC.
Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
Medical condition: Hidradenitis Suppurativa
Disease: Version SOC Term Classification Code Term Level
20.0 100000004858 10020041 Hidradenitis suppurativa LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) HU (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-006709-31 Sponsor Protocol Number: COAV101B12302 Start Date: 2022-08-12
Sponsor Name: Novartis Pharma AG
Full Title: Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101 administered intrathecally (1.2 x 1014 vector genomes) to participants 2 to 12 yea...
Medical condition: Spinal Muscular Atrophy
Disease: Version SOC Term Classification Code Term Level
20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)